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Abstract
Background—Most patients receiving warfarin are man- aged in outpatient office settings or
anticoagulation clinics that require frequent visits for monitoring.
Objective—To measure the amount and value of time required of patients for chronic
anticoagulation therapy with warfarin.
Design/Participants—Prospective observation of a cohort of adult patients treated at a
university-based anticoagulation program.
Measurements—Participants completed a questionnaire and a prospective diary of the time
required for 1 visit to the anticoagulation clinic, including travel, waiting, and the clinic visit. The
authors reviewed subjects’ medical records to obtain additional information, including the
frequency of visits to the anti- coagulation clinic. They used the human capital method to estimate
the value of time.
Results—Eighty-five subjects completed the study. The mean (median) total time per visit was
147 minutes (123). Subjects averaged 15 visits per year (14) and spent 39.0 hours (29.3) per year
on their visits. Other anticoagulation-related activities, such as communication with providers,
pharmacy trips, and extra time preparing food, added an average of 52.7 hours (19.0) per year. The
mean annual value of patient time spent traveling, waiting, and attending anticoagulation visits
was $707 (median $591). The mean annual value when also including other anticoagulation-
related activities was $1799 (median $1132).
Conclusions—The time required of patients for anticoagulation visits was considerable,
averaging approximately 2.5 hours per visit and almost 40 hours per year. Methods for reducing
patient time requirements, such as home-based testing, could reduce costs for patients, employers,
and companions.
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Long-term anticoagulation therapy with warfarin is the mainstay of treatment for venous
thrombosis, pulmonary embolism, atrial fibrillation and cardiac valve replacement, with
close to 4 million patients taking warfarin in the United States.1 Due to warfarin's narrow
therapeutic window and the potential for bleeding or thromboembolic complications,
frequent monitoring of the international normalized ratio (INR) is required. Most patients
receiving warfarin are managed in outpatient office settings or anticoagulation clinics that
require frequent visits for INR monitoring. Thus, the time required of patients may be
substantial.
Patient time costs are an important factor in comparing the cost-effectiveness of alternative
approaches to warfarin therapy, such as self-monitoring at home and anticoagulation clinic-
based management. In addition, they may be an important factor for deciding about whether
to use anticoagulation therapy with warfarin v. other treatments (aspirin, no treatment, or
low molecular weight heparin in some situations). The consensus Panel on Cost-
Effectiveness in Health and Medicine recommends the incorporation of patient time costs in
economic analyses.2-5 Measuring and valuing patient time and including it in cost-
effectiveness models has been shown to have an important impact on cost-effectiveness
results.6-8 Previously published models have either not included or not reported patient time
or have used crude estimates of patient time.8-10
Although some studies have reported the amount of patient time related to a variety of other
health care activities,3,5,11,12 we found none that have done so adequately for chronic
anticoagulation therapy with warfarin. The aim of this study was to use prospective time
diaries to measure the patient time requirements for visits (including travel and waiting) for
chronic anticoagulation therapy with warfarin and to estimate the economic value of that
time. In addition, we sought to measure and value the time patients spend on other
anticoagulation-related activities, including communicating with the anticoagulation clinic,




We enrolled patients from a university-based anticoagulation program within our General
Internal Medicine practice between April and November 2007. At that time, our
anticoagulation program pro- vided care for 410 patients. The mean age of these patients
was 61.4 years (range, 20–93), 59% were male, 62% were white, 30% were African
American, and 88% were insured. Our clinic is part of a tertiary care center in a state with a
large rural population. All INR testing was done by point-of-care fingerstick using the
CoaguChek S meter in our clinic.
The study research assistant (RA) reviewed the daily schedule to identify potentially eligible
patients, who were then approached in person. After verifying eligibility, the RA obtained
informed consent and presented the study materials. Patients were eligible for inclusion if
they were at least 18 years old, on chronic stable warfarin therapy for at least 3 months, and
able to complete the study materials. We excluded patients with antiphospholipid antibody
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syndrome (APLA) due to different treatment (and time) requirements for care and patients
who were unable to complete the study materials by themselves or with assistance from our
RA or a family member. We also excluded non- English-speaking patients without a friend
or family member who could translate for them.
The RA generally spent 2 out of 5 weekdays recruiting subjects. The days of the week spent
recruiting varied from month to month. The RA attempted to recruit consecutive patients,
but once he began enrolling one subject, he would not be able to approach other potential
subjects because of the time required for enrollment and questions. Each day of the week
had a similar contribution to our total sample.
Patients who completed the study received a $20 gift card. The study was approved by the
University of North Carolina's Biomedical Institutional Review Board.
Measures
Participants were asked to complete a written questionnaire and keep a diary that recorded
the time requirements for one visit to the anticoagulation clinic, including travel, waiting,
and the clinic visit.
We used previous studies6,7,13-15 and the expertise of our team to develop our diary and
questionnaire. We pretested the diary and questionnaire with 10 patients at the study site.
The study RA asked patients to read and complete the questionnaires, explaining out loud
how they would interpret and answer the questions. Changes were made to the diary and
questionnaire based on this feedback.
Subjects enrolled in the study were asked to use a formatted time diary to note the time
when 4 steps in the anticoagulation clinic visit process occurred (Appendix 1). Items
recorded included when they departed home (or other location) to go to the clinic, arrived at
the front desk of the clinic, checked out at the front desk, and arrived at home (or other
destination) after the visit. Subjects were instructed to record whether or not they stopped for
any reason (such as food or another appointment) between when they left home and arrived
home. They were asked to provide the reasons and amounts of time spent for each stop so
that this time would not be included. We did not collect data to separate waiting time from
time spent receiving services while in the clinic, but such data from a patient flow analysis
in our clinic have been published previously.16 Subjects were provided with the time diary
at the time of enrollment (visit 1, the index anticoagulation clinic visit) and instructed to
complete the diary prospectively during their next anticoagulation clinic visit (visit 2). They
were called 2 days prior to the next visit (visit 2) to remind them to complete the diary. After
completion, subjects returned the diary to the RA using a self-addressed, postage-paid
envelope or in person when they returned to the clinic (visit 3).
The questionnaire was to be completed for the same anticoagulation clinic visit as the diary.
It included questions about the overall visit experience, activities missed due to the visit, and
time spent in activities related to anticoagulation (Appendix 2). To estimate the incremental
time cost for warfarin management compared with other care, we asked patients how much
time they spend for each of the following: communicating with the anticoagulation clinic by
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phone or e-mail, getting their warfarin from the pharmacy (for trips or phone calls), and
extra time spent on diet and food preparation because of their anticoagulation. We also
asked questions about the following themes: travel costs, the patient's companion,
demographic information, occupational history, annual household income, and health
(including self-rated overall health and past medical history).
We reviewed subjects’ medical records to obtain the following information: age, frequency
of visits to the anticoagulation clinic over the year prior to the index visit, duration of
warfarin therapy, warfarin dose, time in therapeutic range (how often their INR was at goal),
and indication(s) for warfarin. Time in therapeutic range was calculated as the proportion of
INRs within 0.2 of the target range. For example, for subjects with a target range of 2 to 3,
values from 1.8 to 3.2 were considered in range.
We used the Rapid Estimate of Adult Literacy in Medicine (REALM) to measure literacy.17
The REALM is a reading cognition assessment tool designed to measure literacy by
assessing a patient's recognition of health care terms. It takes approximately 3 minutes to
complete.
Data Analysis
We described reported time requirements by means, medians, and ranges. We excluded
subjects not returning the diary and questionnaire from our analyses. We examined
differences in the time requirements for anticoagulation clinic visits (including travel and
waiting) by age, sex, race, educational attainment, income, insurance, employment status,
health literacy, travel distance, duration of warfarin therapy, reason for anticoagulation, and
time in therapeutic range. We tested these bivariate comparisons using nonparametric
statistics because the data were not normally distributed for the key outcome (time). We
calculated medians and P values using Wilcoxon rank sum for variables with 2 categories
and Kruskal-Wallis for variables with more than 2 categories. We calculated correlations
with time for continuous variables using Spearman's correlation. We then conducted
multivariate analyses using linear regression; models included all variables found to have
significant (P < 0.05) associations with time in bivariate analyses.
We used the human capital method to estimate the value of patients’ time. The human
capital method, recommended by the Panel on Cost-Effectiveness in Health and Medicine,2
is based on the following economic reasoning: if a person can choose how many hours to
work for pay, he or she will choose to work until the gain from the last hour (the wage)
equals the value he or she places on using that hour for unpaid activities.18 Thus, as an
approximation, the wage rate indicates the value of the person's time at the margin (i.e., for
small changes in activities). If the person chooses not to work, that indicates that he or she
values unpaid activities more highly than the market wage he or she could command. Thus,
we valued time by multiplying it by the wage rate. To represent a population perspective, we
used $19.29 per hour, the national average wage from the June 2006 National Compensation
Survey.19 Based on the above reasoning, the appropriate value of time for nonworking
hours, or for those outside the workforce, is at least the market wage rate.2 As such, we also
used the national average wage for nonworking hours, including participants who were
homemakers, retired, or unemployed.
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We conducted sensitivity analyses for the annual value of patient time required for
anticoagulation clinic visits, including travel and waiting. Our reference case was based on
the average population wage rate, our subjects’ actual travel times, our subjects’ actual
number of visits, and no companion time. We conducted sensitivity analyses by altering
several factors. First, we changed the wage rate, using our subjects’ personal hourly wages,
to illustrate the value for our participants rather than the general population. Personal hourly
wages were estimated by using the midpoint of the personal annual income range from the
questionnaire ($97,500 was used for the $90,000 or greater category) and dividing by 2080
hours (assuming a 40-hour workweek for 52 weeks per year). Second, we used shorter one-
way travel times reported in other cost-effectiveness models8-10 to illustrate the possible
impact of the relatively long travel times of our subjects. Third, we varied the number of
visits per year to those reported in other cost-effectiveness publications.8-10 Finally, we
calculated the impact of including companion time for the participants who reported having
a companion for their visit.
We also conducted sensitivity analyses for the time spent communicating with the
anticoagulation clinic, getting warfarin from the pharmacy, and for diet and food preparation
by removing responses for reported times that seemed excessively long. For diet and food
preparation, we removed responses of greater than 10 minutes extra per day (16 subjects).
For pharmacy trips, we removed those reporting an average of more than 1 trip per month (9
subjects) and those reporting over 2 hours per trip (8 subjects). For e-mails and phone calls
communicating with anticoagulation providers, we removed those reporting more than 2
communications per month on average (1 subject reporting 8 per month).
Results
We contacted 144 patients through on-site recruiting. Of these, 120 were enrolled in the
study. Thirty-five subjects did not return one or both of the survey materials (diary or
questionnaire). Overall, 85 of the 120 enrolled subjects (71%) completed the study (Figure
1).
Participant characteristics are summarized in Table 1. The mean age of participants was 56.8
years (range, 20–89), 52% were male, 72% were white, 93% were insured, and 46% had
annual household incomes under $30,000. The 35 subjects enrolled who did not complete
the study were similar in age but were more likely to be male, be African American, and
have atrial fibrillation as their indication for anticoagulation. Participants completing the
study were similar to the overall anticoagulation clinic population in age, sex, and insurance
status but were more likely to be white. Subjects averaged 15 visits per year (median 14) to
the anticoagulation clinic.
The amount and value of patient time spent on anticoagulation clinic visits and other
anticoagulation-related activities are shown in Table 2. The mean time required for 1 visit,
including travel and waiting, was 147 minutes. This time was divided among travel to the
clinic (mean 46.6 minutes), time in the clinic for waiting and consultation (mean 56.5
minutes), and travel back home (mean 43.7 minutes). Given the average of 15 visits per
year, we calculated that subjects spent an average of 39 hours for visits, travel, and waiting.
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Subjects spent an average of 52.7 hours on other anticoagulation-related activities annually
(16.4 hours in sensitivity analyses when excluding excessively long responses). From the
human capital method, the mean annual value of patient time spent traveling, waiting, and
attending anticoagulation visits was $707 (median $591). The mean annual value of total
patient time for traveling, waiting, attending visits, and other anticoagulation-related
activities was $1799 (median $1132).
The time required for 1 anticoagulation clinic visit (including travel and waiting) was
sensitive to the following categorical variables: sex, health literacy, employment status,
household income, educational attainment, and whether the patient missed work (Table 3).
Time required for anticoagulation clinic visits was correlated with the following continuous
variables: age, REALM score (health literacy), time in therapeutic range (TTR), and travel
distance. Time requirements decreased with increasing age (correlation −0.29, P = 0.008),
with increasing REALM score (− 0.32, P = 0.003), and with increasing TTR (− 0.30, P =
0.006). Increasing travel distance was correlated with increasing time requirements (0.45, P
< 0.001). In multivariate linear regression, only travel distance and TTR remained
significantly associated with time requirements.
Results of our sensitivity analyses for the annual value of patient time required for
anticoagulation clinic visits are shown in Table 4. Our first sensitivity analysis, using our
subjects’ personal hourly wages, which averaged $16.89, decreased the mean (median)
annual value of patient time required for anticoagulation clinic visits from $707 ($591) to
about $504 ($370). In our next sensitivity analysis, we adjusted the one-way travel time to
20, 30, and 40 minutes. This decreased the mean annual value of patient time to $465
($434), $562 ($530), and $658 ($627), respectively. Adjusting the number of visits per year
to 18 and 24 resulted in an increase in mean annual value to $849 ($709) and $1132 ($945),
respectively. Last, we included companion time for the 26% of subjects who were
accompanied for their visit. This resulted in an increase in mean annual value up to $921
($644) of person time.
Discussion
In this study, the time required of patients for anticoagulation visits (including travel and
waiting) was considerable, averaging approximately 2.5 hours per visit and almost 40 hours
per year. Travel time accounted for almost two thirds of the time related to clinic visits.
When including the time invested by patients’ companions, the total person time required
for anticoagulation visits was about 50 hours per year.
In addition to time spent on visits, patients reported spending a substantial amount of time
on other anticoagulation-related activities, including about 40 hours per year of extra time
for diet and food preparation beyond the amount they would spend if they were not on
warfarin. Our results for the time spent on other anticoagulation-related activities may seem
greater than expected. Our sensitivity analyses (removing responses that seemed excessively
long) found considerably shorter times for diet and food preparation and pharmacy trips,
suggesting that the responses of a small percentage of subjects may have resulted in
overestimates or that a small percentage of subjects spend a much larger than expected
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amount of time on some activities. Notably, even if the time spent on other anticoagulation
activities is not considered, patients treated with warfarin still spent a considerable amount
of time on visits, travel, and waiting.
Management strategies for patients on chronic warfarin therapy include home self-
monitoring (either self-testing with self-management or self-testing with clinician
management), anticoagulation clinic management, and primary care physician management.
Differences in the time required of patients for these different management strategies can
affect their relative cost-effectiveness.8,9 In addition, the time required for treatment is
important information for patients with atrial fibrillation and their providers to make
informed decisions about whether to begin chronic anticoagulation therapy with warfarin v.
aspirin or no treatment.
Although self-monitoring has been reported to be more effective than standard monitoring
(i.e., by anticoagulation clinics or personal physicians), with improvement in both the
benefits and harms related to anticoagulation and a reduction in death from all causes, cost-
effectiveness analyses have reached mixed conclusions about the value of self-
monitoring.8,10,20-30 Some analyses have found self-monitoring to be cost- saving, whereas
others have reported a relatively high cost per quality-adjusted life year (QALY) gained.9
One potential reason for these differences is how these analyses accounted for patient time.
Just 2 out of 7 cost-effectiveness analyses comparing self-monitoring to other models of
managing long-term oral anticoagulation included patient time costs.8,10,27-30 One of these
compared anticoagulation clinic care with patient self-testing.8 The model included 20
minutes of patient time for the anticoagulation clinic visit and 52 minutes of travel time per
patient. When the time and travel costs were included, the incremental cost- effectiveness
ratio for patient self-testing changed from $153,000 per QALY to being cost-saving.
Several previously published studies have focused on measuring the time that patients spend
in health- related activities.6,7,13,31-46 Some measured visit time or clinic time but ignored
travel time, waiting time, or other time invested.40,45 Others have measured time away from
work.36 We tried to measure all the relevant time intervals invested in the anticoagulation
clinic visit process from a patient perspective. In addition, a strength of our study is the
prospective design, with real-time patient experiences recorded in time diaries, thus reducing
the potential for measurement bias and recall bias. Most previous studies measured patient
time using clinic schedules or retrospective surveys.13,14,32,35,36,42,45-48 Few used
prospective patient time diaries,6,7 which may be a better way to obtain reliable data on time
allocation.49
One study with 20 patients measured and reported a component of the time patients spend
monitoring warfarin.31 The study was designed to compare the cost-effectiveness of
monitoring INR using venipuncture v. fingerstick testing (for practice-based
anticoagulation). It aimed to measure only the time and costs for the testing itself rather than
all time related to a visit that included clinical care. It measured patient waiting time for a
nurse, patient/nurse encounter time, and INR testing time. Patients spent an average of 20
minutes for venipuncture testing and 16.2 minutes for fingerstick testing. The difference
between these times and those measured in our study (mean 56.5 minutes, not including
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travel) can be explained by differences in the time intervals that were measured and in the
services provided.
A study using data from the American Time Use Survey (ATUS), a telephone survey
conducted by the Census Bureau for the Bureau of Labor Statistics, determined the average
time costs of outpatient visits (not specific to anticoagulation clinic visits).43 Respondents
were asked how they spent the 24 hours beginning at 4 a.m. the day before the call. During
the first 4 years of the survey (2003-2006), 1621 out of over 60,000 respondents reported
spending an average of 121 minutes on outpatient care.43
The Panel on Cost-Effectiveness in Health and Medicine recommends the incorporation of
patient time costs in economic analyses.2 In addition, it supports the use of the human
capital method, which is dependent on accurate measures of time, to value time.2 Although
time diaries have been considered the gold standard for measuring time,43,49 it is not clear
when other measures, such as retrospective questionnaires, are sufficient. Whether
prospective studies using real-time diaries, which may be time and resource intensive, are
necessary or if information from published retrospective studies or the ATUS should be used
may differ depending on the situation. The ATUS showed that the average total time spent
on an outpatient visit was 121 minutes compared with the mean of 147 minutes (median
123) in our study. But is that difference likely to have enough impact on cost-effectiveness
results to make it worthwhile to do a separate study?
Measuring time prospectively with real-time diaries as we have done is likely the most
accurate method of measuring time because it minimizes the potential for measurement bias
(from recall bias). However, prospective time diaries and 24-hour recall have not been
compared head-to-head for common settings and situations to determine the magnitude of
difference between the 2 methods. Nevertheless, we hypothesize that there are some
circumstances where it is worthwhile for analysts to make the effort to measure patient time
prospectively and others where they could use numbers from other sources.
For cost-effectiveness analyses conducted from the societal perspective, for common health
conditions, it seems reasonable to use published data from retrospective surveys such as the
ATUS for time spent on travel, waiting, and visits. The ATUS has the advantage of
representing subjects from all over the United States, rather than one location as most other
studies of patient time have been. Conversely, surveys such as the ATUS that measure time
in general without obtaining any information about health conditions or the type of provider
seen make it difficult to determine what to attribute the time costs to. If analysts need to
accurately determine patient time costs for a specific condition rather than for visits in
general, then it may be necessary to conduct a separate study. Otherwise, they may be
overestimating time costs by attributing them to just one condition, when the time may be
related to care for several conditions.
The frequency and number of relevant events should be considered in determining whether a
separate study is indicated. For example, treatments that require a large number of visits,
such as radiation oncology treatments for some cancers, may necessitate more accurate
measurement of patient time. This is also the case for anticoagulation therapy with warfarin,
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where small errors in the measurement of time spent per visit would be multiplied many
times when calculating annual time costs. An error of just 10 minutes per visit would lead to
an error of 150 minutes per year (assuming 15 visits per year), worth $48.23 per patient per
year. With close to 4 million patients taking warfarin in the United States, the error in
societal time costs resulting from inaccurate measurement would be substantially large.1
Another important consideration in determining whether a separate study is necessary is
whether there are potential interventions that can do any- thing to improve (often by
reducing) patient time costs. For instance, quality improvement efforts to decrease patient
time spent in care or to improve efficiency, such as to decrease patient waiting times, should
rely on local prospective data rather than previously published literature.
Cost-effectiveness analyses that focus on patients from rural locations may underestimate
travel times if they use data from previously published studies. In our study, for example,
travel times were longer than societal averages (mean approximately 90 minutes in our study
compared with 35 minutes from the ATUS)43 because our clinic is a tertiary care center
located in a relatively rural state. Thus, if one was attempting to determine the cost-
effectiveness of home monitoring compared with anticoagulation clinic care, results may
differ if the analysis considers only rural locations as opposed to urban locations or an
“average” location. For locations where patients have longer travel times, home monitoring
would be more cost-effective than locations where patients have shorter travel times.
Perhaps most important, prior to using their own time and resources, analysts should
consider the potential impact of patient time on the incremental cost-effectiveness ratio. In
situations where patient, companion, or caregiver time invested will be roughly equal among
the options being considered, it is likely not necessary to conduct separate studies to
determine time costs. On the other hand, if large differences in time between the options
being considered are hypothesized, separate studies may be necessary.
Our study has several limitations. First, 29% of subjects did not complete the study, which
may have affected our results. Analyses of the noncompleters do not suggest a clear
direction of this bias. Noncompleters were less likely to be female and less likely to be
insured, which would suggest their time requirements would be greater, according to our
bivariate analyses. However, they were less likely to be white, which would suggest their
time requirements would be less than completers. Next, our study is based on one site with a
structured anticoagulation program that uses fingerstick INR testing. Our anticoagulation
clinic providers and staff have conducted multiple quality improvement activities designed
to improve clinic efficiency. For example, one quality improvement intervention in our
clinic decreased mean visit time (from 84 to 59 minutes) and waiting time between check-in
and INR testing (from 28 to 4 minutes).16 In addition, travel times may be longer than other
sites due to our role as a tertiary care center in a rural state.
Another potential limitation is that our measure may have slightly overestimated travel time.
Although we explicitly asked subjects to record any stops between the time they left home
and arrived home so this time would not be included, we did not explicitly ask them to
include travel time related to the stops. Some of these stops may have been on the route
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home and not added additional travel time; others may have required additional travel time.
About one third (29/85, 34%) of subjects reported stopping for any reason between when
they left home and arrived home. Finally, although the time for travel, waiting, and visits
was measured prospectively in ‘real time,” the time for other anticoagulation-related
activities was based on patient recall of time spent recently and extrapolated to annual
values, introducing possible measurement bias.
In conclusion, the time required of patients for chronic oral anticoagulation is considerable.
Methods for reducing patient time requirements, such as home-based testing or self-
monitoring, could reduce costs for patients, employers, and companions. Analysts should
contemplate their specific context of interest to determine whether it is essential to mea- sure
time prospectively with real-time experiences or if retrospective surveys or general estimates
from other sources will suffice.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Mean age (SD) [range] 56.8 (15.4) [20-89] 58.5 [20-83] 61.4 [20-93]
% Male 52 63 59
Race, %
    White, non-Hispanic 72 54 62
    Black/African American 24 43 30
    Other 4 3 8
Primary reason for anticoagulation, %
    Atrial fibrillation/flutter 43 54 42
    Venous thromboembolism 42 20 44
    Heart valve 14 17 14
% Insured 93 66 88
% Medicare 41 40
% Medicaid 16 11
% Other insurance 69 50
One-way travel distance (miles), mean (SD) [range]
c 16.9 (18.7) [0-100] 15.6 (12.3) [1-45]
Warfarin dose, mg/d, mean (SD) [range] 6.2 (3.5) [0.7-15] 6.1 (3.3) [1.4-13.6]
Time in therapeutic range, %, mean (SD) [range] 58.6 (20.1) [0-100] 59.1 (21.9) [10-94]
Proportion of INRs >4 (or >4.5 for those with target 2.5-3.5), %,
mean (SD) [range]
6.2 (8.6) [0-33] 8.5 (10.1) [0-33]
Employment status, %
    Employed 28
    Unemployed 5
    Housewife/husband 5
    Retired 28
    Disabled 26
    Student 6
    Other 5
Annual household income range, %
    0 to $14,999 33
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Percentage
a





    $15,000 to $29,999 13
    $30,000 to $44,999 11
    $45,000 to $59,999 12
    $60,000 to $74,999 0
    $75,000 to $89,999 5
    $90,000 or greater 26
Education level completed, %
    7th grade or lower 1
    8th to 11th grade 9
    High school graduate or GED 21
    Some college or vocational school 20
    2-year college degree 6
    4-year college degree 20
    Professional or graduate degree 23
General health (self-rated), %
    Excellent 8
    Very good 21
    Good 34
    Fair 29
    Poor 8
INR, international normalized ratio.
a
Percents were rounded to the nearest whole number and may not total 100 due to rounding.
b
Limited characteristics available for noncompleters because most information was obtained from the self-administered questionnaire that they did
not return.
c
One-way travel distance was based on self-report for those returning the questionnaire. For noncompleters, we calculated one-way travel distance
using MapQuest to determine the distance between our clinic and each patient's address of record.
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Table 2
Amount and Value of Patient Time Spent on Anticoagulation Care
Anticoagulation Clinic Visits Mean Time (Median) $ Mean (Median) Value
a
One visit Travel to the clinic 46.6 minutes
Time in clinic (including waiting) 56.5 minutes (50)
Travel back home 43.7 minutes
Total for travel and time in clinic 147 minutes (123)
















Diet and food preparation 40.9 hours (0, 0-274) 9.5 hours
Pharmacy trips 9.4 hours (6, 0-66) 5.5 hours
E-mails and phone calls
communicating with
anticoagulation providers
1.4 hours (0, 0-32) 1.1 hours
Annual total for other
anticoagulation-related activities
52.7 hours (19) 16.4 hours
Overall annual total for anticoagulation clinic visits (including travel
and waiting) and other anticoagulation-related activities
d
93.9 hours (58.7) $1799 ($1132)
a
Value of time calculated using the human capital method with an hourly rate of $19.29.
b
When also including companion time for subjects who had someone accompany them for the visit (26% of subjects), the mean annual time for
visits (including travel and waiting) increased from 39 to 48 hours of person time per year.
c
Data for the times for “other anticoagulation-related activities” were obtained from self-report from the questionnaire (see Web Appendix 2 at
http://mdm.sagepub.com/supplemental) rather than prospectively, thus introducing potential recall bias. Results for some of these times revealed
mean values that were considerably greater than the median values. Thus, we conducted sensitivity analyses removing unlikely responses. For diet
and food preparation, we removed responses of greater than 10 minutes extra per day (16 subjects). For pharmacy trips, we removed those
reporting more than an average of 1 trip per month (9 subjects) and those reporting over 2 hours per trip (8 subjects). For e-mails and phone calls
communicating with anticoagulation providers, we removed 1 subject reporting an average of 8 communications per month. All other subjects
reported between 0 and 2 communications per month for 0 to 60 minutes each, on average.
d
When also including companion time, the mean annual total increased to 100.5 hours, and the mean value increased to $1939.
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Table 3
Bivariate Associations between Patient Characteristics and Time Required for One Anticoagulation Clinic










    3rd grade and below (0-18) 0 0.024
    4th to 6th grade (19-44) 5 190
    7th to 8th grade (45-60) 9 150
    High School (61-66) 71 115
Medicare
    Yes 36 109.5 0.03
    No 50 133.5
Medicaid
    Yes 14 140 0.038
    No 72 115
Other insurance 59 112 0.014
No other insurance 27 140
Current employment status
    Employed 23 105 0.002
    Unemployed 4 142.5
    Housewife/husband 3 100
    Retired 24 94
    Disabled 21 180
    Student 5 115
    Other 4 122.5
Annual household income range
    0 to $14,999 26 150 0.029
    $15,000 to $29,999 11 160
    $30,000 to $44,999 9 100
    $45,000 to $59,999 10 131.5
    $60,000 to $74,999 0
    $75,000 to $89,999 4 117.5
    $90,000 or greater 19 112
Education




























    7th grade or lower 1 150 0.011
    8th to 11th grade 8 190
    High school graduate or GED 18 150
    Some college or vocational school 16 119.5
    2-year college degree 5 125
    4-year college degree 16 101
    Professional or graduate degree 19 100
Missed work 25 105 0.018
Did not miss work 60 133.5
a
Bivariate associations are only shown for those factors with statistically significant associations with time (P < 0.05). Race, target international
normalized ratio range, primary reason for anticoagulation, duration of warfarin therapy, who accompanied the patient, self-rated general health,
insurance status, and satisfaction with the clinic were not significantly associated (P > 0.05).
b
Medians and P values calculated using Wilcoxon rank-sum tests for variables with 2 categories and Kruskal-Wallis tests for variables with more
than 2 categories. For variables with more than 2 categories, the P values reported are those for the entire variable group.
c
REALM scores range from 0 to 66 and are divided into 4 categories: (1) 3rd grade and below, scores of 0 to 18, subject will not be able to read
most low literacy materials and will need repeated oral instructions and materials composed primarily of illustrations or audio- or videotapes; (2)
4th to 6th grade, scores of 19 to 44, will need low literacy materials and may not be able to read prescription labels; (3) 7th to 8th grade, scores of
45 to 60, will struggle with most patient education materials; (4) high school, scores of 61 to 66, will be able to read most patient education
materials.
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Table 4
Sensitivity Analyses for the Annual Value of Patient Time Required for Anticoagulation Clinic Visits,






    Mean US population wage rate of $19.29
    One-way travel time of our subjects (mean, 57 minutes) 39 (29) $707 (591)
    Our subjects’ actual number of visits per year (mean, 15)
    No companion time
Sensitivity analyses
    Using our subjects’ personal hourly wages (mean, $16.89; median, $10.82) Same as reference case $504 (370)
    One-way travel time
        20 minutes $465 (434)
        30 minutes 24 (23) $562 (530)
        40 minutes 29 (28) $658 (627)
    Visits per year 34 (33)
        18 44 (37) $849 (709)
        24 59 (49) $1132 (945)
Including companion time for the 26% of subjects who reported having a companion
for the anticoagulation clinic visit
48 (33) $921 (644)
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